Nike Stock Jumps After Jefferies Upgrade
Shares of Nike advanced about 5%, one of the best performers in the S&P 500 Monday, after Jefferies raised its recommendation on the stock to buy from hold. The investment bank cited Nike Chief Executive Elliott Hill's strategy to reposition the sportswear brand after years of missteps.
Nike Shares Become Top Performer in S&P 500 After Jefferies Upgrades Stock to Buy
Shares of Nike became the best performer in the S&P 500 after Jefferies raised its recommendation on the stock to buy from hold, citing Chief Executive Elliott Hill's strategy to reposition the sportswear brand after years of missteps.
Jefferies analyst Giles Thorne downgraded Just Eat Takeaway.com (JTKWY) to Hold from Buy with a price target of EUR 20.30, down from EUR 22.50, ...
10don MSN
Staffers described an increasingly toxic atmosphere as younger bankers were pushed to their limits to close megabucks M&A ...
Freshpet (NASDAQ:FRPT) gained over 6% in pre-market on Monday as Jefferies upgraded the American pet food company shares to ...
In a report released today, James Wheatcroft from Jefferies maintained a Buy rating on J D Wetherspoon (JDW – Research Report), with a price ...
Investing.com -- Jefferies has downgraded Just Eat Takeaway.com (AS: TKWY) to a "hold" rating following Prosus (OTC: PROSF )' ...
The suspected cause of death for a Jefferies banker found dead in his apartment has been revealed as it's claimed he was working 100 hours a week. Carter McIntosh, 28, was discovered dead on his ...
The Jefferies analyst feels capacity utilization could reach 94% from the current 88%. They note that when utilization was last that high from 2019 to 2020, day rates hit a stunning $95,000 daily.
Allworth Financial LP grew its stake in shares of Jefferies Financial Group Inc. (NYSE:JEF – Free Report) by 163.1% during ...
The torrent of retail funds flowing into India’s equity mutual funds is at risk of abating as market returns decline, according to Jefferies Financial Group Inc. A slowdown in households ...
Jefferies initiated coverage of Wave Life Sciences (WVE) with a Buy rating and $26 price target Wave is a clinical stage biotech focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback